A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.

MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium tuberculosis antigens designed to boost BCG-induced immunity. Clinical trials with candidate malaria vaccines have demonstrated that adenoviral vector based priming immunisation, followed b...

Full description

Bibliographic Details
Main Authors: Sharon Sheehan, Stephanie A Harris, Iman Satti, David A Hokey, Veerabadran Dheenadhayalan, Lisa Stockdale, Zita-Rose Manjaly Thomas, Alice Minhinnick, Morven Wilkie, Samantha Vermaak, Joel Meyer, Matthew K O'Shea, Maria Grazia Pau, Isabella Versteege, Macaya Douoguih, Jenny Hendriks, Jerald Sadoff, Bernard Landry, Paul Moss, Helen McShane
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4631471?pdf=render

Internet

http://europepmc.org/articles/PMC4631471?pdf=render

Similar Items